Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Lupin Limited - Product Pipeline Review - 2014

Published: Feb-2014 | Format: PDF | Global Markets Direct | Number of pages: 38 | Code: MRS - 998

This report provides comprehensive information on the current therapeutic developmental pipeline of Lupin Limiteds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


The report provides brief overview of Lupin Limited including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Lupin Limiteds human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Lupin Limiteds pipeline products

Reasons to buy

Evaluate Lupin Limiteds strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Lupin Limited in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Lupin Limiteds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Lupin Limited and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lupin Limited
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Lupin Limited and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Lupin Limited Snapshot 5
Lupin Limited Overview 5
Key Information 5
Key Facts 5
Lupin Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Lupin Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Lupin Limited - Pipeline Products Glance 12
Lupin Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lupin Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Lupin Limited - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Lupin Limited - Drug Profiles 16
(budesonide + formoterol fumarate + tiotropium bromide) 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Biosimilar for Cancer 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
LND-101001 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Biosimilar for Inflammation 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Biosimilar for Osteoporosis 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Biosimilar for Rheumatoid Arthritis 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Biosimilar for Viral Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule for Auto-Immune Diseases 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule for Diabetes 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecule for Pain and Inflammation 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule for Viral Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lupin Limited - Pipeline Analysis 28
Lupin Limited - Pipeline Products by Target 28
Lupin Limited - Pipeline Products by Route of Administration 29
Lupin Limited - Pipeline Products by Molecule Type 30
Lupin Limited - Pipeline Products by Mechanism of Action 31
Lupin Limited - Dormant Projects 32
Lupin Limited - Company Statement 33
Lupin Limited - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34

Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38 

List of Tables

Lupin Limited, Key Information 5
Lupin Limited, Key Facts 5
Lupin Limited - Pipeline by Indication, 2014 8
Lupin Limited - Pipeline by Stage of Development, 2014 9
Lupin Limited - Monotherapy Products in Pipeline, 2014 10
Lupin Limited - Combination Treatment Modalities in Pipeline, 2014 11
Lupin Limited - Phase III, 2014 12
Lupin Limited - Phase II, 2014 13
Lupin Limited - Preclinical, 2014 14
Lupin Limited - Discovery, 2014 15
Lupin Limited - Pipeline by Target, 2014 28
Lupin Limited - Pipeline by Route of Administration, 2014 29
Lupin Limited - Pipeline by Molecule Type, 2014 30
Lupin Limited - Pipeline Products by Mechanism of Action, 2014 31
Lupin Limited - Dormant Developmental Projects,2014 32
Lupin Limited, Other Locations 34
Lupin Limited, Subsidiaries 35 

List of Figures

Lupin Limited - Pipeline by Top 10 Indication, 2014 7
Lupin Limited - Pipeline by Stage of Development, 2014 9
Lupin Limited - Monotherapy Products in Pipeline, 2014 10
Lupin Limited - Pipeline by Top 10 Target, 2014 28
Lupin Limited - Pipeline by Top 10 Route of Administration, 2014 29
Lupin Limited - Pipeline by Top 10 Molecule Type, 2014 30
Lupin Limited - Pipeline Products by Top 10 Mechanism of Action, 2014 31

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing